Products

Afinitor^®

Afinitor (everolimus) tablets has been approved for the treatment of patients with advanced renal cell carcinoma,
whose disease has progressed on or after treatment with
VEGF-targeted therapy.

• In cancer cells, Afinitor continuously targets mTOR, a protein that acts as a central regulator of tumor cell division, cell metabolism and blood vessel growth.

This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.

www.afinitor.com/global »
(For Non U.S. Health Care Professionals Only)

www.afinitor.com »
(For U.S. Residents Only)

EXJADE^®

EXJADE (deferasirox) is a Novartis Oncology drug indicated for the treatment of chronic iron overload due to frequent blood transfusions in patients with beta thalassaemia major aged 6 years and older.

EXJADE is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:

• in patients with other anemias,
• in patients aged 2 to 5 years,
• in patients with beta thalassaemia major with iron overload due to frequent blood transfusions.

This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.

www.exjade.com »
(For Non U.S. Health Care Professionals Only)

www.us.exjade.com »
(For U.S. Residents Only)

Femara^®

Femara (letrozole tablets) is indicated for the treatment of:

• Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
• Extended adjuvant treatment of hormone dependent early breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy for 5 years.
• First-line treatment in postmenopausal women with hormone-dependent advanced breast cancer.
• Advanced breast cancer in women with natural or artificially induced postmenopausal status after relapse or disease progression, who have previously been treated with antiestrogens.

This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.

www.femarainfo.com »
(For Non U.S. Health Care Professionals Only)

www.femara.com »
(For U.S. Residents Only)

Glivec^®

Glivec (imatinib), which is known as "Gleevec" in the United States, is a cancer treatment indicated for:

• Adult and pediatric patients with newly diagnosed Ph+ Chronic Myeloid Leukemia for whom bone marrow transplantation is not considered as the first line of treatment.
• Adult and pediatric patients with Ph+ Chronic Myeloid Leukemia in chronic phase after failure of interferon-alfa therapy, or in accelerated phase or blast crisis.
• Adult patients with newly diagnosed Ph+ ALL integrated with chemotherapy.
• Adult patients with relapsed or refractory Ph+ ALL as monotherapy.
• Adult patients with myelodysplastic syndrome/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene rearrangements.
• Adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFRa rearrangement.

Glivec is also indicated for:

• Adult patients with Kit (CD117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST)
• Adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery

This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.

www.glivec.com »
(For Non U.S. Health Care Professionals Only)

www.gleevec.com »
(For U.S. Residents Only)

Sandostatin^® LAR^®

Sandostatin LAR (octreotide/IM injection) is indicated for the treatment of:

Of patients with acromegaly:

• who are adequately controlled on s.c. treatment with Sandostatin
• in whom surgery or radiotherapy is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective

Treatment of patients with symptoms associated with functional GEP NE in whom symptoms are adequately controlled on s.c. treatment with Sandostatin:

Carcinoid tumours with features of the carcinoid syndrome.

• VIPomas
• Glucagonomas
• Gastrinomas (Zollinger-Ellison syndrome)
• Insulinomas-for pre-operative control of hypoglycemia as well as maintenance therapy
• GRFomas

This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.

www.sandostatin.com »
(For Non U.S. Health Care Professionals Only)

www.us.sandostatin.com »
(For U.S. Residents Only)

Tasigna^®

Tasigna (nilotinib) is a cancer treatment for Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic or accelerated phase in patients resistant to, or experiencing significant toxicity during cancer treatment with, imatinib.

This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.

www.tasigna.com »
(For Non U.S. Health Care Professionals Only)

www.us.tasigna.com »
(For U.S. Residents Only)

ZOMETA^®

Zometa is indicated for the prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcameia) in patients with advanced malignancies involving bone.

• Treatment of tumor-induced hypercalcemia

This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.

www.zometa.com »
(For Non U.S. Health Care Professionals Only)

www.us.zometa.com »
(For U.S. Residents Only)